Literature DB >> 27447098

Phenotypes of California CF Newborn Screen-Positive Children with CFTR 5T Allele by TG Repeat Length.

Danieli Barino Salinas1, Colleen Azen2, Suzanne Young3, Thomas G Keens1, Martin Kharrazi4, Richard B Parad5.   

Abstract

BACKGROUND: At the cystic fibrosis transmembrane conductance regulator (CFTR) gene (IVS8)-(TG)m(T)n locus, a lower number of thymidines (legacy names 9T vs. 7T vs. 5T) and a higher number of (TG) repeats (TG-11 vs. 12 vs. 13) are associated with decreasing translation of functional CFTR protein in vitro.
METHODS: Retrospective cohort study comparing phenotypes of California CF newborn screen-positive children (followed 2-8 years) who had two CF-causing mutations (diagnosed as CF) with those who had one mutation from a panel of 40 CF-causing mutations (CF40mut) and one (IVS8)-(TG)11, 12, or 13-5T mutation detected by sequencing (diagnosed as CFTR-related metabolic syndrome [cRMS]).
RESULTS: The study included 428 children, of which 234 had two CF-causing mutations, and were used to compare with the other 194 children with one CF-causing mutation and one isolated 5T allele [CF40mut/(TG)13-5T = 21, CF40mut/(TG)12-5T = 85, and CF40mut/(TG)11-5T = 88]. Among children with CF40mut/(TG)13-5T, 38% were diagnosed with CF by 8 years, based on sweat chloride results and clinical presentation. Six percent of those with CF40mut/(TG)12-5T, and none with CF40mut/(TG)11-5T, reached diagnostic criteria.
CONCLUSIONS: CFTR (IVS8)-(TG)m-5T allele (TG) tract length determination provides valuable information in predicting the risk of developing a CF phenotype. Of the three types of 5T alleles evaluated, screen-positive children with genotype CF40mut/(TG)13-5T progressed from CRMS to CF at a high rate, while there was little evidence of clinical disease in those with CF40mut/(TG)11-5T. Additional data from longer follow-up intervals are needed to fully understand the natural history of individuals with a CF40mut/(TG)m-5T genotype.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27447098      PMCID: PMC5395019          DOI: 10.1089/gtmb.2016.0102

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  27 in total

1.  Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.

Authors:  Drucy Borowitz; Richard B Parad; Jack K Sharp; Kathryn A Sabadosa; Karen A Robinson; Michael J Rock; Philip M Farrell; Marci K Sontag; Margaret Rosenfeld; Stephanie D Davis; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

2.  Benign outcome among positive cystic fibrosis newborn screen children with non-CF-causing variants.

Authors:  Danieli Barino Salinas; Patrick R Sosnay; Colleen Azen; Suzanne Young; Karen S Raraigh; Thomas G Keens; Martin Kharrazi
Journal:  J Cyst Fibros       Date:  2015-03-29       Impact factor: 5.482

3.  Impact of IVS8-(TG)m(T)n on IRT and sweat chloride levels in newborns identified by California CF newborn screening.

Authors:  Steven Keiles; Ruth Koepke; Richard Parad; Martin Kharrazi
Journal:  J Cyst Fibros       Date:  2011-12-30       Impact factor: 5.482

4.  Recommendations for the classification of diseases as CFTR-related disorders.

Authors:  C Bombieri; M Claustres; K De Boeck; N Derichs; J Dodge; E Girodon; I Sermet; M Schwarz; M Tzetis; M Wilschanski; C Bareil; D Bilton; C Castellani; H Cuppens; G R Cutting; P Drevínek; P Farrell; J S Elborn; K Jarvi; B Kerem; E Kerem; M Knowles; M Macek; A Munck; D Radojkovic; M Seia; D N Sheppard; K W Southern; M Stuhrmann; E Tullis; J Zielenski; P F Pignatti; C Ferec
Journal:  J Cyst Fibros       Date:  2011-06       Impact factor: 5.482

5.  Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign.

Authors:  Joshua D Groman; Timothy W Hefferon; Teresa Casals; Lluís Bassas; Xavier Estivill; Marie Des Georges; Caroline Guittard; Monika Koudova; M Daniele Fallin; Krisztina Nemeth; Gyorgy Fekete; Ludovit Kadasi; Ken Friedman; Martin Schwarz; Cristina Bombieri; Pier Franco Pignatti; Emmanuel Kanavakis; Maria Tzetis; Marianne Schwartz; Giuseppe Novelli; Maria Rosaria D'Apice; Agnieszka Sobczynska-Tomaszewska; Jerzy Bal; Manfred Stuhrmann; Milan Macek; Mireille Claustres; Garry R Cutting
Journal:  Am J Hum Genet       Date:  2003-12-18       Impact factor: 11.025

6.  A variable dinucleotide repeat in the CFTR gene contributes to phenotype diversity by forming RNA secondary structures that alter splicing.

Authors:  Timothy W Hefferon; Joshua D Groman; Catherine E Yurk; Garry R Cutting
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-01       Impact factor: 11.205

7.  Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis.

Authors:  B Stewart; J Zabner; A P Shuber; M J Welsh; P B McCray
Journal:  Am J Respir Crit Care Med       Date:  1995-03       Impact factor: 21.405

8.  Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Authors:  Drucy Borowitz; Karen A Robinson; Margaret Rosenfeld; Stephanie D Davis; Kathryn A Sabadosa; Stephanie L Spear; Suzanne H Michel; Richard B Parad; Terry B White; Philip M Farrell; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

9.  Comprehensive genetic analysis of the cystic fibrosis transmembrane conductance regulator from dried blood specimens--implications for newborn screening.

Authors:  Anja Kammesheidt; Martin Kharrazi; Steve Graham; Suzanne Young; Michelle Pearl; Charles Dunlop; Steven Keiles
Journal:  Genet Med       Date:  2006-09       Impact factor: 8.822

10.  Extensive sequencing of the cystic fibrosis transmembrane regulator gene: assay validation and unexpected benefits of developing a comprehensive test.

Authors:  Charles M Strom; Donghui Huang; Christina Chen; Arlene Buller; Mei Peng; Franklin Quan; Joy Redman; Weimin Sun
Journal:  Genet Med       Date:  2003 Jan-Feb       Impact factor: 8.822

View more
  4 in total

1.  Abnormal Lung Clearance Index in Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) Children with Otherwise Normal FEV1.

Authors:  Ajay S Kasi; Choo Phei Wee; Thomas G Keens; Danieli B Salinas
Journal:  Lung       Date:  2019-12-16       Impact factor: 2.584

Review 2.  Inconclusive Diagnosis after Newborn Screening for Cystic Fibrosis.

Authors:  Anne Munck
Journal:  Int J Neonatal Screen       Date:  2020-03-12

3.  CRMS/CFSPID Subjects Carrying D1152H CFTR Variant: Can the Second Variant Be a Predictor of Disease Development?

Authors:  Vito Terlizzi; Rita Padoan; Laura Claut; Carla Colombo; Benedetta Fabrizzi; Marco Lucarelli; Sabina Maria Bruno; Alice Castaldo; Paolo Bonomi; Giovanni Taccetti; Antonella Tosco
Journal:  Diagnostics (Basel)       Date:  2020-12-12

4.  Elucidating clinical phenotypic variability associated with the polyT tract and TG repeats in CFTR.

Authors:  Keith Nykamp; Rebecca Truty; Darlene Riethmaier; Julia Wilkinson; Sara L Bristow; Sienna Aguilar; Dana Neitzel; Nicole Faulkner; Swaroop Aradhya
Journal:  Hum Mutat       Date:  2021-07-10       Impact factor: 4.700

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.